Consistently, the FXR agonist GW4064 was reported to increase STAT3 activation in endometriotic stromal cells, whereas FXR inhibitor Z-GS treatment suppressed both STAT3 phosphorylation and activities in multiple myeloma cells [34, 35]. Here, NR1H4 is linked to plasma cell myeloma.